Schwinger R H, Böhm M, Erdmann E
Medizinische Klinik I, Universität München, FRG.
Am Heart J. 1990 Apr;119(4):899-904. doi: 10.1016/s0002-8703(05)80329-1.
It is well established that increasing degrees of heart failure are accompanied by a reduced density of myocardial beta-adrenoceptors. It is unclear, however, whether all beta-adrenoceptors in the cardiac cell membrane are coupled to the effector system or whether "spare receptors" or "uncoupled" beta-adrenoceptors also exist. To investigate this, we measured the density of beta-adrenoceptors and the positive inotropic response to isoprenaline in preparations from the same human hearts. The myocardium from nonfailing hearts had significantly (p less than 0.01) higher numbers of beta-adrenoceptors (104 +/- 7 fmol/mg protein) compared with tissue from moderately (mitral valve disease, New York Heart Association [NYHA] class II to III, 60 +/- 2.8 fmol/mg protein) and terminally (dilated cardiomyopathy, NYHA class IV, 35 +/- 2.7 fmol/mg protein) failing human hearts. The KD values of the drug-receptor complexes did not differ within the different patient groups. There was a linear relationship (r = 0.97) between the beta-adrenoceptor density measured and the maximally obtainable positive inotropic effect elicited by isoprenaline in the three groups tested. Thus there seem to be no spare beta-adrenoceptors, that is, receptors not required for the production of the maximal inotropic response in the left ventricular human myocardium, and there are no uncoupled beta-adrenoceptors. The beta-adrenoceptors associated with the plasma membrane (marker: 3H-ouabain binding sites) remained functionally active. In addition, these results indicate that either there is no amplifier system behind the receptor level or it remains unchanged in the failing left ventricular human myocardium under the conditions tested.
心力衰竭程度的加重伴随着心肌β-肾上腺素能受体密度的降低,这一点已得到充分证实。然而,尚不清楚心肌细胞膜上的所有β-肾上腺素能受体是否都与效应器系统偶联,或者是否也存在“备用受体”或“未偶联”的β-肾上腺素能受体。为了研究这一问题,我们在取自同一人心脏的标本中测量了β-肾上腺素能受体的密度以及对异丙肾上腺素的正性肌力反应。与中度(二尖瓣疾病,纽约心脏协会[NYHA] II至III级,60±2.8 fmol/mg蛋白质)和终末期(扩张型心肌病,NYHA IV级,35±2.7 fmol/mg蛋白质)心力衰竭患者的心脏组织相比,非衰竭心脏的心肌β-肾上腺素能受体数量显著更多(p<0.01,104±7 fmol/mg蛋白质)。不同患者组中药物-受体复合物的KD值没有差异。在所测试的三组中,测量的β-肾上腺素能受体密度与异丙肾上腺素引起的最大可获得正性肌力效应之间存在线性关系(r = 0.97)。因此,似乎不存在备用β-肾上腺素能受体,即在人左心室心肌产生最大正性肌力反应时不需要的受体,也不存在未偶联的β-肾上腺素能受体。与质膜相关的β-肾上腺素能受体(标志物:3H-哇巴因结合位点)仍保持功能活性。此外,这些结果表明,要么在受体水平之后不存在放大系统,要么在所测试的条件下,人左心室衰竭心肌中的放大系统保持不变。